Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: PR Newswire
According to DelveInsight's analysis, the chronic refractory cough market size is expected to increase due to an increase in disease prevalence, the growth in the market of currently approved products, and the expected launch of emerging therapies such as MK-7264 (gefapixant), ORV-PF-01, camlipixant/BLU-5937, AX-8, and others during the forecast period. LAS VEGAS, Nov. 20, 2024 /PRNewswire/ -- Chronic refractory cough (CRC) is characterized by a cough that persists for more than 8 weeks, even with treatment following established protocols. Patients with this condition may need assistance from multiple medical specialties. Those affected frequently experience a reduced quality of life, impacting their daily activities.As per DelveInsight analysis, in 2023 the 12-month prevalent cases of chronic cough in the 7MM were estimated to be approximately 30 million cases, out of which the US accounted for nearly 13 million cases. These cases are expected to increase during the forecast period (
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsightPR Newswire
- Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]Yahoo! Finance
- Verona Pharma Announces December 2024 Investor Conference ParticipationGlobeNewswire
- Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]Yahoo! Finance
- Actimed Therapeutics Announces Professor David Ebsworth to Become Executive ChairmanGlobeNewswire
VRNA
Sec Filings
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- 12/2/24 - Form 4
- VRNA's page on the SEC website